 Glucosylceramidase
"Glucosylceramidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycosidase that hydrolyzes a glucosylceramide to yield free ceramide plus glucose. Deficiency of this enzyme leads to abnormally high concentrations of glucosylceramide in the brain in GAUCHER DISEASE. EC 3.2.1.45.
| Descriptor ID |
D005962
|
| MeSH Number(s) |
D08.811.277.450.420.475.400
|
| Concept/Terms |
Glucosylceramidase- Glucosylceramidase
- Glucocerebrosidase
- Glucocerebroside beta-Glucosidase
- Glucocerebroside beta Glucosidase
- beta-Glucosidase, Glucocerebroside
- Glucosyl Ceramidase
- Ceramidase, Glucosyl
- Glucosylceramide beta-Glucosidase
- Glucosylceramide beta Glucosidase
- beta-Glucosidase, Glucosylceramide
- Glucosylsphingosine Glucosyl Hydrolase
- Glucosyl Hydrolase, Glucosylsphingosine
- Hydrolase, Glucosylsphingosine Glucosyl
- Acid beta-Glucosidase
- Acid beta Glucosidase
- beta-Glucosidase, Acid
- beta-Glucocerebrosidase
- beta Glucocerebrosidase
|
Below are MeSH descriptors whose meaning is more general than "Glucosylceramidase".
Below are MeSH descriptors whose meaning is more specific than "Glucosylceramidase".
This graph shows the total number of publications written about "Glucosylceramidase" by people in UAMS Profiles by year, and whether "Glucosylceramidase" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 0 | 1 | 1 | | 2017 | 2 | 1 | 3 | | 2016 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 1998 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucosylceramidase" by people in Profiles over the past ten years.
-
Oliver R, Sallam AB, Uwaydat SH. Retinal Deposits in a Young Woman. JAMA Ophthalmol. 2018 06 01; 136(6):708-709.
-
Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Am J Hematol. 2017 Sep; 92(9):929-939.
-
Pandey MK, Burrow TA, Rani R, Martin LJ, Witte D, Setchell KD, Mckay MA, Magnusen AF, Zhang W, Liou B, K?hl J, Grabowski GA. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017 03 02; 543(7643):108-112.
-
Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Goker-Alpan O, Watman N, El-Beshlawy A, Kishnani PS, Pedroso ML, Gaemers SJM, Tayag R, Peterschmitt MJ. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017 04 27; 129(17):2375-2383.
-
Elstein D, Burrow TA, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee HM, Mellgard B, Zimran A. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease. Mol Genet Metab. 2017 Jan - Feb; 120(1-2):111-115.
-
Kattoor AJ, Bauer TW, Berkowitz M, Polster JM, Lichtin AE. Ankle pain in a young woman with Gaucher disease. Cleve Clin J Med. 2015 Sep; 82(9):607-13.
-
Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015 Jun 13; 385(9985):2355-62.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|